Abstract 95P
Background
To compare the pathological complete response rates and toxicity in patients receiving long-course neoadjuvant chemoradiotherapy versus total neoadjuvant therapy in locally advanced carcinoma rectum.
Methods
Biopsy-proven newly diagnosed patients of locally advanced rectal adenocarcinoma clinical tumor stage were randomized. Arm A patients received short-course radiotherapy (25 Gy in 5 fractions over seven days) followed by six cycles of CAPEOX chemotherapy (Capecitabine 825 mg/m2 orally twice daily D1-D14 and oxaliplatin 130 mg/m2 on day 1) at intervals of 21 days. Arm B patients received concurrent chemoradiation (50.4 Gy in 28 fractions, five fractions in a week with concurrent tablet capecitabine 825 mg/m2 orally twice daily). Total Mesorectal Excision was done in both arms 6 to 8 weeks after completion of neoadjuvant treatment.
Results
60 patients were included in the study, 30 patients in each arm. Both arms were balanced in terms of the age of the patient, sex, stage of the disease, and tumor location. The median interval between randomization and surgery was 32 weeks and 20 weeks in the experimental arm and control arm, respectively. 9 out of 30 (33.3%) patients in the experimental arm and 6 out of 30 (20%) patients in the control arm had Pathological complete responses (p=0.682). At a median follow-up of 12 months, 6 out of 30 patients developed distant metastases in the standard arm as compared to 1 out of 15 patients in the experimental arm. Grade 3 or higher gastrointestinal adverse events were higher in the experimental arm (20%) as compared to (7%) in the standard arm (p-value=0.59). The requirement of colostomy during surgery was 46% in arm A as compared to 55.5% in arm B (p-value=1.0). Table: 95P
MRI response | ARM A | ARM B |
T3-> T1/2 | 33% | 26% |
T4-> T1/2 | 6.6% | - |
T4-> T3 | 26% | 20% |
T3-> T0 | 6.6% | - |
N2-> N0 | 26% | 20% |
N1-> N0 | 33% | 20% |
Pathological response | ARM A | ARM B |
pT0 | 33.3% | 20% |
pT1 | 20% | 20% |
pT2 | 6.6% | 13.3% |
pT3 | 26.6% | 20% |
pN0 | 80% | 53.3% |
pN1 | 13.3% | 40% |
pN2 | 6.6% | 6.6% |
Conclusions
Total neoadjuvant therapy in locally advanced carcinoma rectum had a higher complete pathological response than the standard arm. The survival analysis of the trial is awaited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
All India Institute of Medical Sciences, Intramural Funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract